Kidney Health Gateway
Back to all trials
Currently Enrolling
Interventional

ADU-CL-19

A study of BION-1301 in Adults with IgA Nephropathy

Brief Description

The ADU-CL-19 study is testing BION-1301, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy.

Trial Physician / Study Coordinator

Hanna Thomas

Email Phone 214-538-4262
Site Name

Liberty Research Center / Dallas Renal Group
8200 Matlock Road, Suite 160, Arlington, TX 76002

Sponsor

Chinook Therapeutics, Inc.

Study Drug

BION-1301

Estimated enrollment

Up to 40

Estimated end date

April 2024

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Find other locations for this trial:
Currently Enrolling
Interventional

ADU-CL-19

A study of BION-1301 in Adults with IgA Nephropathy

Brief Description

The ADU-CL-19 study is testing BION-1301, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy.

Trial is for people with

Primary IgA Nephropathy (IgAN)

Study Goal

The goal of this study is to find out whether BION-1301 can safely and tolerably reduce the amount of protein in urine for patients with IgA nephropathy.

What is involved for the Patient?

Patients will be asked to allow researchers to access medical history, collect blood and urine samples, and perform safety assessments like physical examinations, blood pressure and weight checks, and electrocardiograms. If they are eligible for the study, participants will be asked to come to clinic every 2 weeks for up to 1 year to receive the study drug and, at some visits, collect additional blood and urine samples and safety assessments.

About the drug or intervention

BION-1301 may help reduce proteinuria levels by targeting A-proliferation-inducing ligand (APRIL), a protein that is found in higher levels in people with IgA nephropathy and may worsen their kidney disease. BION-1301 is administered as a subcutaneous (under the skin) injection.

Find other locations for this trial:
Arlington, TX
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

See other frequently asked questions